KBKristian Bolin

Kristian Bolin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kristian Bolin has a total of 72 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Burden of Stroke: Incidence, Hospitalizations, Mortality, and Life-Years Lost in Sweden during 2000–2022

    by Kristian Bolin, Katharina Stibrant Sunnerhagen

    Background and aims: There are no estimates of the disease burden and economic burden of stroke in Sweden for (>2) consecutive years. The objective of this study is to derive estimates of the “annual” disease and economic burden of stroke in Sweden for the years 2000–2022. Methods: This study employs total population Swedish register data pertaining to hospital-based care, mortality and sickness-absenteeism reimbursement due to stroke for the period 2000–2022 in order to estimate the disease and economic burden of stroke. The annual economic burden of stroke was calculated for the years 2000–2022, using unit costs based on data from Statistics Sweden and the Swedish National Board of Health and Welfare, and reported in 2022 prices. Results: The incidence of stroke among males aged 50 to 60% during the same period. The decrease in mortality corresponds to a reduction in annual expected lost working years by about 50%. The annual number of reimbursed days of sickness absenteeism is about the same at the end of the study period as at the beginning. The direct economic burden of stroke was estimated at about Eur 0.51 billion annually, while indirect costs (productivity losses) decreased from Eur 0.31 billion to Eur 0.24 billion. Thus, the total economic burden of stroke declined from Eur 0.84 billion in 2000 to Eur 0.74 billion in 2022. Conclusions: The decline in the economic burden of stroke over the study period reflects improved stroke treatment.

  • Open Access

    CHANGE IN STROKE SURVIVAL in Sweden 2000 – 2022 – the importance of sex, attained education and age

    by Kristian Bolin, Katharina S Sunnerhagen

    Background: The time trend in long-term survival after a stroke is to some extent unknow due to (relatively) short follow up periods in available data. The objective of this study is to identify and quantify differences in long-term stroke survival in Sweden between men and women and patients with different attained educational levels, comparing two time-periods, 2000-2009 and 2010-2022. Methods: This study employs total population Swedish register data pertaining to hospital-based care and mortality due to stroke for the period 2000–2022 in order to estimate survival (all-cause mortality) after ischaemic and haemorrhagic stroke, respectively, and pertaining to attained educational level. Kaplan-Meier survival functions are estimated stratifying for time-period, sex and educational level. Cox regressions are employed to quantify mortality hazard ratios between the strata. Age is taken into account in complementary analyses (supplement). Results: Taking only time-period (2000-2009 vs 2010-2022) into account resulted in significantly higher survival in the second period for ischaemic stroke patients (HR: 0.84; 95% CI: 0.83-0.84), while no significant difference could be detected for haemorrhagic stroke. Stratifying for sex showed that men gained more than women in terms of reduced mortality hazard rate between the periods. Further stratifying by educational level and estimating survival separately for men and women showed that, for both men and women, patients with the lowest education were relatively worse off (compared to patients with higher education) in the second period. Further analyses, taking age into account, reversed the relative hazard ratio between men and women, but corroborated the result that low education is associated with poorer outcome than high education. Conclusions: The results suggest that there are considerable differences in expected long-term survival after stroke between the sexes, but that this may be due to differences in age between the sexes at the time of stroke. Moreover, lower educational level is significantly associated with lower long-time survival.

  • Open Access

    Trends in Hospitalisations Due to Respiratory Syncytial Virus in Swedish Children: A Nationwide Study 2010–2022

    by Kristian Bolin, Karin Strandell, Andreas Palmborg, Sofie Gustafsson, Sven‐Arne Silfverdal

    Aim: Respiratory syncytial virus (RSV) infection is a leading cause of paediatric hospitalisations. This study describes annual RSV‐hospitalisation burden of disease, by gestational week of delivery, age and sex among children aged 0–17 years of age in Sweden, for the period 2010/11–2021/22. Methods: Employing total population Swedish register data pertaining to hospitalisations due to RSV for the period 2010–2022. Results: Over the study period a total of 26 772 children were hospitalised due to RSV. Most of the patients, 63.2%, were aged < 6 months and 39.9% were aged < 3 months. Among patients aged < 3 months, 88.5% were born at full term. The average number of hospital days increased with lower gestational age at birth for all age groups, except for patients aged 5‐ ≤ 17 years of age. Estimated incident rate ratios (IRR) comparing patients born at full term to patients born extremely preterm ranged between 2.43 and 1.75, respectively, for patients aged 0 < 3 months and 1 < 2 years of age. Conclusions: Paediatric RSV hospitalisations mostly occur in the youngest infants, and most are born at term. Gestational age at birth and age at admission are both negatively related to length of stay.

  • Open Access

    Treatment of epilepsy using newer antiseizure medications: A retrospective cohort study of prescription patterns in Sweden 2013–2022

    by Kristian Bolin, Patric Berling, Torbjörn Tomson

    Objective: This study aimed to analyze the choice of newly introduced antiseizure medications (ASMs; brivaracetam, cannabidiol, cenobamate, fenfluramine, and perampanel) by age and sex, and the use of these ASMs in relation to regulatory approval. Methods: Patients were identified with dispensation of any ASM subsequent to at least one health care contact due to epilepsy (International Classification of Diseases, 10th Revision: G40) during 2000–2022. Incidence rate ratios (IRRs) for starting a newly introduced ASM, retention rates, number of ASM treatments preceding the first dispensation of a new ASM and concurrent ASM treatments at first dispensed new ASM, and share of patients using new ASMs as adjunctive treatment were calculated. Results: Three percent of all patients identified with epilepsy treatment during the period 2013–2022 used at least one new ASM. IRRs for ever being dispensed a new ASM differed between age groups for all ASMs except cenobamate. The corresponding IRRs associated with sex were insignificantly different from 1, except for cannabidiol; men were more likely to start using cannabidiol. One‐year retention rates were between 42% (cannabidiol, men) and 64% (brivaracetam, men). The majority (70%) of patients had used >2 ASMs prior to the first dispensation of a new ASM, and a majority (98%) of patients were treated with another ASM at first dispensation of a new ASM (≤90 days before). Similarly, 82% of the patients who started using a new ASM did so as an adjunctive treatment (ASMs dispensed ≤90 days before and ≥90 days after first new ASM). Significance: Our observations indicate that prescription patterns of the newer ASMs comply with the currently approved indications for the respective medications for a majority of patients (prevalence of brivaracetam as adjunctive treatment is somewhat lower). Retention on the dispensed medications are in line with what would be expected for adjunctive treatment of patients with drug‐resistant epilepsies.


  • Open Access

    Specification of the health production function and its behavioral implications

    by Kristian Bolin, Michael R. Caputo

    The health production function of the canonical health‐capital model is generalized to allow the state of health to affect the total and marginal products of health investment. If the total and marginal products of health investment are nonincreasing functions of the state of health, then the solution of the generalized model is locally qualitatively identical to that of the canonical model. Moreover, and in contrast to the canonical model, the generalized model is able to rationalize the cycling of the state of health and health investment observed in some individuals. The necessary conditions on the health production function for cyclical behavior are identified as well.


  • Open Access

    Valproic acid and socioeconomic associations in Swedish women with epilepsy 2010–2015

    by Klara Andersson, Anneli Ozanne, Kristian Bolin, Torbjörn Tomson, Johan Zelano

    Objective We investigated the correlation between socioeconomic status and the prescription of Valproic acid (VPA) in women of fertile age in Sweden. Methods This is a registered‐based cohort study including all women living in Sweden aged 18‐45 years in the years 2010–2015, with a diagnosis of epilepsy and no intellectual disability (n = 9143). Data were collected from the National Patient Register, the Drug Prescription Register, and the Longitudinal integration database for health insurance and labor market studies (LISA). Results Women with only 9 years of school were more often prescribed VPA than women with a University degree (12.9% compared to 10.7% in 2015 [p = 0.015]). Similar differences were seen between the lowest and highest income group (16.6% compared to 12.7% in 2015 [p < 0.001]). The odds of having a VPA prescription in 2015 was 1.59 (p < 0.001) in women with 9 years of school compared to women with a University degree, and 1.60 (p < 0.001) in the lowest income group relative to the highest income group after adjusting for age. From 2010 to 2015, the proportion with VPA prescription in the whole cohort diminished with an absolute reduction of −2.2% (p < 0.001). The decrease was similar among the different education and income groups (p = 0.919 and p = 0.280). Significance The results indicate that the increased knowledge on VPA teratogenicity was implemented across socioeconomic strata in the Swedish healthcare system. Women with lower income or education level remained more frequent VPA users. Whether this difference reflects epilepsy type or severity, or socioeconomic disparities, merit further study.


  • Open Access

    Healthcare costs and productivity losses associated with county‐based home‐care service for sick children in Sweden

    by Charlotte Castor, Kristian Bolin, Helena Hansson, Kajsa Landgren, Inger Kristensson Hallström

    Aims: The aim of this study was to estimate the healthcare costs and productivity losses associated with county‐based home‐care services (HCS) for sick children.Methods: In this observational follow‐up study, a combination of hospital care and HCS was compared to estimated alternative care solely at the hospital. Data on one year of healthcare utilisation for 32 children, supplied by the hospital and HCS, were collected from administrative systems. Corresponding healthcare unit prices were collected from healthcare pricelists. The human‐capital approach was applied to estimate productivity losses and the value of productivity losses for 25 parents. Family characteristics, including parental work absenteeism and income, were collected by a questionnaire distributed to parents at five time points during a year. Descriptive and comparative statistics were used for analysis and carried out with ethical approval.Results: Healthcare costs for children receiving a combination of hospital care and HCS varied among children with estimated average healthcare cost savings of SEK 50 101 per child compared to the alternative of care provided only in the hospital. The reduced costs were related to children receiving nonpalliative HCS care tasks. Average annual productivity losses due to parental work absenteeism were estimated at 348 hours with an associated monetary value estimated at SEK 137 524 per parent.Conclusion: County‐based HCS, provided as complement to and substitute for hospital care for ill children, does not increase healthcare cost and should be a prioritized area when organising paediatric health care. Productivity losses vary greatly among parents and are pronounced also when children receive HCS with signs of gender‐related differences.


  • The cost utility of pitolisant as narcolepsy treatment

    by Kristian Bolin, Per‐Åke Niska, Laura Pirhonen, Pontus Wasling, Anne‐Marie Landtblom

    Objectives The cost‐effectiveness of available pharmacological treatments for narcolepsy is largely unknown. Available pharmacological treatments are associated with tolerability, abuse and adherence issues. Pitolisant is the first inverse agonist of the histamine H3 receptor to be prescribed for the treatment of narcolepsy with and without cataplexy. Studies suggest that pitolisant is both as effective as previously introduced drugs and is associated with fewer adverse effects. The objective in this study was to estimate the cost‐effectiveness of pitolisant as monotherapy, and pitolisant as an adjunctive treatment to modafinil, compared to standard treatment. Materials & Methods Calculations were performed using a Markov model with a 50‐year time horizon. Healthcare utilisation and quality‐adjusted life years (QALYs) for each treatment alternative were calculated assuming no treatment effect on survival. Probabilistic sensitivity analyses were performed for treatment effectiveness and healthcare cost parameters. Results The cost per additional quality‐adjusted life year was estimated at SEK 356 337 (10 SEK ≈1 Euro) for pitolisant monotherapy, and at SEK 491 128 for pitolisant as an adjunctive treatment, as compared to standard treatment. The cost‐effectiveness measure was demonstrated to be particularly sensitive to the assumptions made concerning indirect effects on total healthcare utilization and the pitolisant treatment cost. Conclusions The incremental cost‐effectiveness ratios were below the unofficial willingness‐to‐pay threshold at SEK 500 000. The estimated costs per additional QALY obtained here are likely to overestimate the true cost‐effectiveness ratio since significant potential indirect effects – pertaining both to labour‐market and household‐related productivity – of treatment are not taken into account.